Mycoplasma pneumoniae infection is a rare condition and usually associated with a severe clinical course. We here report a case of a young man with a clinical diagnosis of severe ITP secondary to M. pneumoniae infection. The clinical features, therapy and outcome are presented.
INTRODUCTION
Immune thrombocytopenia (ITP) is one of the more common causes of thrombocytopenia in otherwise healthy adults. Thrombocytopenia associated with M. pneumoniae infection is a rare condition which usually has a severe course. We report the case of a young man with a clinical diagnosis of severe ITP that was associated with M. pneumoniae infection. Extra-pulmonary features of M. pneumoniae infection occur in 20-25% of cases, with the most commonly associated haematological abnormality being haemolytic anaemia due to the formation of cold agglutinin antibodies against erythrocyte I antigen [1] . Thrombocytopenia associated with M. pneumoniae is usually associated with thrombotic thrombocytopenic purpura or disseminated intravascular coagulation, but association with ITP is rare.
CASE DESCRIPTION
A 24-year-old male college student was admitted to the emergency department with a 1-day history of reddish lesions on both legs (Fig. 1) , a tongue haematoma following accidental bite (Fig. 2) and two small back bruises, self-induced after pinching himself. He remembered having odynophagia and serous rhinorrhoea without a cough or fever 2 weeks before admission. With a history of infectious mononucleosis at the age of 16, he had had recurrent tonsillitis ever since. He was physically very active and his medication history included protein supplements and a one-time-only use of sildenafil.
Initial evaluation revealed normal vital signs, with a body temperature of 36.7°C, blood pressure of 132/61 mmHg, pulse rate of 54 beats/ min and O 2 saturation of 100% on room air. He had petechial and purpuric lesions on both legs, slightly palpable hepatosplenomegaly and no identifiable adenopathies. The remaining physical examination was normal. Complete blood count showed haemoglobin of 14.6 g/dl, leucocyte count of 5.7×10 9 cells/l and platelet count of 3×10 9 cells/l. Coagulation, liver and renal studies were normal. CRP was 1.15 mg/dl. A peripheral blood smear confirmed severe thrombocytopenia without abnormal cells. A chest x-ray did not show any signs of pleuroparenchymal lung disease and abdominal ultrasound confirmed the presence of moderate homogeneous hepatosplenomegaly. A presumptive diagnosis of ITP was made, corticoid treatment was promptly initiated and the patient was hospitalized. No platelet count response was seen following a 3-day course of methylprednisolone 1 g IV. Oral prednisolone 1 mg/kg/day and a 3-day course of intravenous immunoglobulin (IVIG) 1 g/kg was therefore initiated with an increase in platelet count to 48×10 9 cells/l the day after. However, on the very next day, the platelet count dropped once again to 2×10 9 cells/l. A second 3-day course of methylprednisolone 1 g IV in association with 4 more days of IVIG 1 g/kg was given with no platelet response. The patient remained clinically stable until the 11th day of hospitalization when he presented with epistaxis ( Fig. 3) , gingival haemorrhage, vascular puncture site haematoma (Fig. 4) and new petechiae on the face and trunk. Prednisolone dosage was increased to 1.5 mg/kg/day and the anti-CD20 monoclonal antibody rituximab 375 mg/m 2 IV was also initiated. Bone marrow examination revealed normal cellularity with megakaryocytic hyperplasia but no cell abnormalities, compatible with the diagnosis of ITP. A thoraco-abdomino-pelvic CT scan did not show any lymphadenopathies or lesions suggestive of a neoplastic process. Serological testing for EBV, CMV, HCV, HBV, HIV, HSV and parvovirus B19 was negative for acute infection. A urea breath test for Helicobacter pylori was negative. Assays for ANA, dsDNA, rheumatoid factor, anticardiolipin, lupus anticoagulant and anti-beta-2 glycoprotein were also negative. Antiplatelet antibodies were positive and a positive M. pneumoniae IgM titre was found. ITP secondary to M. pneumoniae infection was assumed, and clarithromycin 500 mg twice a day was added to the treatment regimen. By the 14 th day of hospitalization the platelet count was still 4×10 9 cells/l and the patient presented with gross haematuria. As a consequence, two pools of platelets were given and he was transferred to the intermediate care unit for closer observation. He became hypertensive (blood pressure of 170/90 mmHg), anaemic (with haemoglobin dropping to 8.9 g/dl) and developed a constant headache and occasional haemolacria (Fig. 5) . A cranial CT scan excluded any haemorrhagic lesions. Six days after the second dose of rituximab (on the 24th day of hospitalization), the platelet count slowly started to rise to 21×10 9 cells/l. Given the subsequent resolution of haematuria and other haemorrhagic dyscrasia, the dose of oral prednisolone was reduced to 1 mg/kg/ day and the patient was transferred back to the medicine ward, where he completed treatment with rituximab. From the 25th day of hospitalization onwards, the platelet count gradually increased, as did haemoglobin values. The patient was discharged on the 28th day after admission with a platelet count of 229×10 9 cells/l and no signs of blood dyscrasia. He returned for 2-week follow-up asymptomatic and with a platelet count of 273×10 9 cells/l, slowly tapering oral prednisolone as advised upon discharge.
DISCUSSION
Haematological abnormalities associated with Mycoplasma infection are widely described, but association with ITP is rarely reported [2] . We identified 10 similar case reports in a literature research. Table 1 summarizes the clinical features and outcomes of those cases. Most patients (7 out of 10) were male and the mean age was 18 years (ranging from 7 months to 64 years). The most common clinical presentation was respiratory infection (cough, fever and dyspnoea) and mild haemorrhagic manifestations (petechiae, purpura and epistaxis). Two patients presented with more severe forms of haemorrhage (haemoptysis, haematuria and haematochezia), while three patients did not have any haemorrhagic symptoms at all. The mean platelet count on admission was 11×10 3 cells/l. Apart from one patient, all subjects underwent corticosteroid therapy. In three of them IGIV therapy was given as well. Empiric antimicrobial therapy was administered to eight patients, targeting atypical bacteria, in most cases through macrolide usage. Interestingly, none of the patients required rituximab. The mean time required for platelets to rise above 150×10 3 cells/l was 21 days. In most cases evidence for Mycoplasma infection came from a complement fixation test, cold agglutinin test or IgM titre. Two patients experienced intracranial haemorrhage and died. Although incompletely understood, the pathogenesis of ITP is thought to involve the formation of specific autoantibodies against platelet cell membrane glycoproteins, more commonly GPIIb/IIIa [3] . In up to 60% of patients, M. pneumoniae infection manifests itself only by odynophagia and rhinorrhoea, as in our patient. Several physiopathological mechanisms have been described to explain the production of antiplatelet antibodies following Mycoplasma infection, such as molecular mimicry, the development of immune complexes that may cause platelet aggregation, serotonin release, and clearance of platelets [4] and even direct binding of Mycoplasma to the platelets, generating a complex that is then recognized as foreign by the immune system. Secondary ITP associated with M. pneumoniae infection appears to have a more severe clinical course and, to some extent, to be a refractory disease, as evidenced by the referenced cases and our own. About 66% of patients with ITP respond to steroid therapy after 1-2 weeks. Our patient was found to be corticosteroid resistant which first led to the need to initiate IGIV therapy and later, given the poor clinical response, to second-line therapy with rituximab. Rituximab is a monoclonal antibody directed against the B cell surface protein CD20. Response to this therapy can occur within a week but may take up to 2 months. In this case our patient had a partial response on day 14 and a complete response after 15 days of rituximab therapy. Specific anti-Mycoplasma therapy was initiated but, in our case, had no apparent effect on the clinical course or outcome, so given the very few cases described, we cannot evaluate the benefit of this particular therapy. [7] 17 Pugliese et al. [9] Okoli et al. [13] 64 
CONCLUSION

